17:20 EST Coya Therapeutics (COYA) files to sell 1.38M shares of common stock for holders Don't Miss our Black Friday Offers: Discover the latest stocks recommended by top Wall Street analysts ...

Coya Therapeutics, Inc.'s stock has sold off on misinterpreted data from a small trial with COYA 301. The presented clinical data validates safety, tolerability, and the inverse dose response of ...

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety ...

Coya Therapeutics (COYA) announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 1.379M shares of its common stock in a private ...

An investigator has posted data on Coya Therapeutics’ COYA 301, linking the IL-2 asset to improvements in biomarkers and cognition on secondary and exploratory endpoints in a small Alzheimer’s ...

(Reuters) - Coya Therapeutics said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with ...

Coya Therapeutics (NASDAQ:COYA) shares tumbled 23% Tuesday after the company reported mixed results from a Phase 2 clinical trial of its therapy candidate LD IL-2 in the treatment of Alzheimer’s ...

Coya Therapeutics, Inc. ( (COYA)) just unveiled an announcement. Coya Therapeutics has announced a change in leadership with Dr. Arun Swaminathan stepping in as CEO, following Dr. Howard Berman ...

https://www.tipranks.com/news/company-announcements/akero-therapeutics-advances-in-mash-treatment-trials Coya Therapeutics, Inc. ( (COYA) ) has issued an update. Coya ...

HOUSTON, November 19, 2024--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing ...

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared ...